Insulet Corporation PODD SPX

Healthcare · Medical Devices · United States

https://www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Market & Price

Market Cap

$10.04B

Current Price

$144.94

High / Low (52W)

$352.82 / $142.65

Beta

1.20

Valuation

Stock P/E

33.86

Industry PE

23.65

Forward P/E

17.92

PEG Ratio

1.10

Book Value

$21.53

Price to Book

6.73

P/S

3.46

EV/EBITDA

17.56

Dividend Yield

Profitability & Returns

ROCE

15.89%

ROE

23.00%

ROA

9.74%

Profit Margin

10.44%

Op Margin

16.03%

EPS (Latest Qtr)

$1.30

EPS (TTM)

$4.28

Balance Sheet & Liquidity

Debt/Equity

0.78

Quick Ratio

1.49

Current Ratio

2.49

Debt

$1.01B

Total Assets

$3.19B

Current Assets

$1.91B

Working Capital

$1.23B

Ownership

Promoter Holding

0.32%

Chg in Prom Hold

FII / Inst Holding

105.31%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$10.57B

Total Revenue (TTM)

$2.90B

EBITDA

$602.00M

Free Cash Flow

$253.38M

Operating Cash Flow

$619.30M

Shares Outstanding

69.26M

Gross Margin

71.01%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

27.54%

Profit 5Y

277.32%

Revenue (YoY)

33.90%

Earnings (YoY)

159.00%

PROS

Strong return on equity of 23.0%.
Compounding revenue at 27.5% over 5 years.
Profit CAGR of 277.3% over 5 years.
Generates positive free cash flow.

CONS

Trading 58.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PODD Insulet Corporation SPX	144.94	33.86	$10.04B	-	15.89%	23.00%	27.54%	277.32%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	101.71M	109.76M	121.78M	130.52M	123.60M	124.20M	151.10M	164.90M	159.60M	177.10M	192.10M	209.40M	198.00M	226.30M	234.00M	249.50M	259.90M	261.80M	247.00M	243.90M	281.90M	261.30M	-	-	-	-	-	-	569.00M	649.10M	706.30M	783.80M	761.70M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	159.90M	196.90M	196.20M	215.20M	232.70M
Gross Profit	30.52M	31.57M	41.99M	44.05M	50.46M	55.64M	60.94M	59.40M	64.64M	73.62M	79.51M	75.80M	82.10M	102.00M	110.30M	106.70M	116.40M	123.10M	134.10M	126.90M	142.50M	151.80M	167.50M	182.70M	188.70M	209.70M	190.30M	188.30M	240.50M	264.90M	293.30M	306.80M	330.90M	-	-	409.00M	452.20M	510.10M	568.60M	529.10M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	320.30M	331.10M	392.40M	422.30M	406.90M
Operating Income	-14.06M	-14.79M	-12.62M	-7.70M	-1.29M	2.42M	-4.13M	-5.31M	-3.36M	2.05M	-768.00K	0	4.33M	6.87M	16.23M	7.30M	7.60M	17.00M	-	7.50M	27.50M	23.80M	16.30M	26.30M	33.70M	37.90M	-26.70M	2.90M	27.70M	31.10M	54.80M	56.90M	54.50M	-	-	88.70M	121.10M	117.70M	146.30M	122.20M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79.10M	70.30M	160.40M	179.50M	153.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.20M	19.60M	15.60M	14.90M	14.70M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.20M	28.40M	122.80M	140.20M	113.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.70M	5.90M	35.20M	38.50M	21.90M
Net Income	-15.43M	-18.93M	-27.33M	-12.48M	-4.20M	-3.08M	-9.12M	-9.98M	-7.77M	-2.23M	-6.86M	-6.60M	-1.70M	1.70M	9.90M	4.40M	1.40M	800.00K	5.00M	-2.10M	14.40M	11.60M	0	-25.00M	12.60M	27.80M	-35.00M	-5.20M	23.80M	27.30M	51.90M	51.50M	188.60M	-	-	35.40M	22.50M	87.60M	101.60M	91.10M
Diluted EPS	-	-	-	-	-	-	-	-	-	-0.04	-	-0.11	-0.03	0.03	0.16	0.07	0.02	0.01	0.08	-0.03	0.22	0.17	0.00	-0.37	0.18	0.40	-0.50	-0.08	0.34	0.39	0.74	0.73	2.59	-	-	0.50	0.32	1.24	1.44	1.30
R&D Expense	12.07M	10.04M	-	12.99M	12.95M	13.73M	-	17.50M	18.03M	20.14M	-	20.27M	18.80M	22.34M	-	32.50M	33.00M	31.30M	-	35.50M	34.20M	38.80M	40.70M	40.10M	37.50M	43.10M	42.60M	45.00M	50.10M	55.10M	57.80M	50.20M	53.90M	54.90M	-	59.60M	73.40M	77.20M	-	89.70M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	366.99M	463.80M	563.80M	738.20M	904.40M	-	1.31B	1.70B	2.07B	2.71B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	499.70M	537.20M	625.90M	768.20M
Gross Profit	18.30M	43.73M	66.71M	92.34M	112.40M	127.13M	133.27M	211.09M	277.20M	370.20M	480.30M	582.30M	-	805.60M	1.16B	1.45B	1.94B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	768.00M	939.80M	1.14B	1.47B
Operating Income	-59.36M	-38.63M	-42.47M	-35.97M	-29.14M	-8.87M	-48.74M	-10.70M	-7.40M	27.40M	50.00M	51.50M	-	37.60M	220.10M	308.90M	473.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	109.00M	323.70M	423.70M	489.30M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	36.00M	36.20M	42.70M	59.40M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	9.80M	214.70M	300.20M	339.50M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	5.20M	8.30M	-118.10M	92.40M
Net Income	-72.34M	-61.16M	-45.83M	-51.87M	-44.97M	-51.50M	-73.52M	-28.88M	-26.80M	3.30M	11.60M	6.80M	-	4.60M	206.30M	418.30M	247.10M
Diluted EPS	-	-	-	-	-	-	-	-0.48	-0.46	0.05	0.19	0.10	-	0.07	2.94	5.78	3.48
R&D Expense	13.23M	16.57M	21.86M	24.36M	21.77M	27.90M	43.21M	55.71M	75.70M	94.80M	132.30M	146.80M	160.10M	180.20M	205.00M	219.60M	301.10M

Compounded Sales Growth

5 Years:	27.54%
1 Year:	33.90%

Compounded Profit Growth

5 Years:	277.32%
1 Year:	159.00%

Stock Price Performance

1 Year:	-55.41%
6 Months:	-55.93%
3 Months:	-41.23%
1 Month:	-9.42%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Jun 2011	Sep 2011	Dec 2011	Mar 2012	Jun 2012	Sep 2012	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	156.23M	238.75M	228.34M	221.32M	215.68M	203.68M	203.38M	198.06M	287.95M	297.18M	275.13M	456.65M	816.74M	840.00M	928.70M	1.14B	1.87B	-	2.25B	2.59B	3.09B	3.19B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.31B	1.58B	1.89B	1.91B
Cash & Equivalents	56.66M	128.00M	113.27M	-	-	93.95M	-	-	-	57.29M	149.73M	151.19M	122.67M	137.17M	272.58M	-	113.90M	213.70M	907.20M	-	674.20M	704.20M	953.30M	716.10M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	346.80M	402.60M	430.40M	452.60M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	205.60M	356.50M	355.80M	511.30M
Total Liabilities	-	-	90.00M	133.31M	133.56M	138.59M	145.46M	144.59M	152.93M	153.88M	163.36M	213.35M	241.07M	393.50M	658.23M	661.12M	716.60M	1.07B	1.27B	1.49B	1.77B	1.86B	1.88B	-
Current Liabilities	-	-	18.95M	-	-	28.00M	-	-	-	48.29M	42.37M	44.30M	65.16M	55.70M	86.03M	88.65M	115.70M	157.70M	207.80M	-	364.70M	451.20M	528.40M	680.10M
Long Term Debt	-	-	69.43M	-	-	108.54M	-	-	-	103.73M	113.65M	164.02M	171.70M	332.77M	566.17M	-	592.00M	887.90M	1.04B	-	1.37B	1.37B	1.30B	930.80M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.40B	1.42B	1.38B	949.20M
Total Equity	28.11M	61.91M	66.23M	105.44M	94.78M	82.73M	70.22M	59.09M	50.45M	44.18M	124.60M	83.83M	34.05M	63.10M	158.50M	178.88M	212.10M	75.90M	603.60M	-	476.40M	732.70M	1.21B	1.52B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	69.51M	69.91M	70.20M	70.59M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-49.32M	-35.62M	-25.45M	-29.06M	3.35M	8.92M	-12.55M	15.91M	41.30M	35.90M	98.40M	84.00M	-	119.00M	145.70M	430.20M	569.30M
Investing Cash Flow	-3.14M	-6.55M	-48.97M	-10.99M	-7.31M	-11.49M	-15.32M	-178.01M	-210.80M	-184.50M	-73.60M	14.00M	-	-191.10M	-119.40M	-146.20M	-222.70M
Financing Cash Flow	123.80M	27.45M	55.10M	3.39M	96.39M	4.03M	-371.00K	176.57M	304.50M	-8.70M	73.50M	605.50M	-	-40.30M	-13.60M	-28.00M	-595.30M
Capital Expenditure	-3.14M	-6.55M	-11.11M	-10.99M	-7.31M	-11.49M	-10.61M	-22.11M	-73.80M	-157.40M	-163.70M	-129.00M	-	-157.30M	-109.20M	-134.00M	-219.40M
Free Cash Flow	-52.46M	-42.17M	-36.57M	-40.05M	-3.96M	-2.57M	-23.16M	-6.20M	-32.50M	-121.50M	-65.30M	-45.00M	-	-38.30M	36.50M	296.20M	349.90M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-112.40M	12.60M	256.00M	-248.80M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	59.60M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	57.5%	59.8%	65.7%	65.1%	64.4%	-	61.7%	68.3%	69.8%	71.6%
Operating Margin %	-	-	-	-	-	-	-	-2.9%	-1.6%	4.9%	6.8%	5.7%	-	2.9%	13.0%	14.9%	17.5%
Net Margin %	-	-	-	-	-	-	-	-7.9%	-5.8%	0.6%	1.6%	0.8%	-	0.4%	12.2%	20.2%	9.1%
ROE %	-116.9%	-92.3%	-55.4%	-117.4%	-36.1%	-61.4%	-215.9%	-45.8%	-16.9%	1.6%	15.3%	1.1%	-	1.0%	28.2%	34.5%	16.3%
ROCE %	-	-28.1%	-22.0%	-24.0%	-11.9%	-3.5%	-23.2%	-2.7%	-1.0%	3.4%	5.1%	3.1%	-	2.0%	10.3%	12.1%	18.9%

Shareholding Pattern

Insiders

0.32%

Institutions

105.31%

Public Float

105.65%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.21%	6.38M	$924.13M
2	Vanguard Capital Management LLC	6.61%	4.58M	$663.72M
3	FMR, LLC	5.74%	3.97M	$576.09M
4	Vanguard Portfolio Management LLC	4.98%	3.45M	$500.04M
5	State Street Corporation	4.39%	3.04M	$440.97M
6	BAILLIE GIFFORD & CO	2.93%	2.03M	$294.15M
7	Geode Capital Management, LLC	2.92%	2.03M	$293.60M
8	T. Rowe Price Investment Management, Inc.	2.62%	1.82M	$263.17M
9	Capital Research Global Investors	2.41%	1.67M	$241.99M
10	AQR Capital Management, LLC	2.31%	1.60M	$231.72M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PODD

No recent headlines available.

PODD · Healthcare